Skip to main content
. 2019 Nov 18;9(4):2045894019849394. doi: 10.1177/2045894019849394

Fig. 3.

Fig. 3.

Individual changes in clinical and hemodynamic parameters after riociguat administration. Change in 6MWD (a*, P = 0.045), NYHA FC (b, P = 0.031), cardiac output (c, P = 0.022), and quality of life (d†, P = 0.021) from baseline to follow-up. Patients 4 and 9 are not depicted in (a–d) as no follow-up data were obtained due to premature study discontinuation. *Short 6MWD in patient 1 is attributed to frailty. †Ten lines visible due to identical quality of life values from patients 5 and 6.